Iovance Biotherapeutics' strong Q3 earnings and promising drug pipeline suggest growth potential for risk-tolerant investors.

More consumers than ever before care about the environmental impact of the products they buy – and that’s proving to be a big challenge ... “Clear labelling aims to address this challenge, and OPRL ...

In a report released today, Patrick Wood from Morgan Stanley maintained a Buy rating on Insulet (PODD – Research Report), with a price ...